Preclinical development of Meta-[At-211]astatobenzylguanidine ([At-211]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (NB).
Publication
, Conference
Batra, V; Makvandi, M; Ranieri, P; Tsang, M; Hou, C; Li, Y; Vaidyanathan, G; Maris, J; Pryma, D
Published in: JOURNAL OF NUCLEAR MEDICINE
May 1, 2015
Duke Scholars
Published In
JOURNAL OF NUCLEAR MEDICINE
EISSN
1535-5667
ISSN
0161-5505
Publication Date
May 1, 2015
Volume
56
Issue
3
Location
Baltimore, MD
Publisher
SOC NUCLEAR MEDICINE INC
Conference Name
Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Batra, V., Makvandi, M., Ranieri, P., Tsang, M., Hou, C., Li, Y., … Pryma, D. (2015). Preclinical development of Meta-[At-211]astatobenzylguanidine ([At-211]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (NB). In JOURNAL OF NUCLEAR MEDICINE (Vol. 56). Baltimore, MD: SOC NUCLEAR MEDICINE INC.
Batra, Vandana, Mehran Makvandi, Pietro Ranieri, Matthew Tsang, Catherine Hou, Yimei Li, Ganesan Vaidyanathan, John Maris, and Daniel Pryma. “Preclinical development of Meta-[At-211]astatobenzylguanidine ([At-211]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (NB).” In JOURNAL OF NUCLEAR MEDICINE, Vol. 56. SOC NUCLEAR MEDICINE INC, 2015.
Batra V, Makvandi M, Ranieri P, Tsang M, Hou C, Li Y, et al. Preclinical development of Meta-[At-211]astatobenzylguanidine ([At-211]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (NB). In: JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC; 2015.
Batra, Vandana, et al. “Preclinical development of Meta-[At-211]astatobenzylguanidine ([At-211]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (NB).” JOURNAL OF NUCLEAR MEDICINE, vol. 56, no. 3, SOC NUCLEAR MEDICINE INC, 2015.
Batra V, Makvandi M, Ranieri P, Tsang M, Hou C, Li Y, Vaidyanathan G, Maris J, Pryma D. Preclinical development of Meta-[At-211]astatobenzylguanidine ([At-211]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma (NB). JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC; 2015.
Published In
JOURNAL OF NUCLEAR MEDICINE
EISSN
1535-5667
ISSN
0161-5505
Publication Date
May 1, 2015
Volume
56
Issue
3
Location
Baltimore, MD
Publisher
SOC NUCLEAR MEDICINE INC
Conference Name
Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging
Related Subject Headings
- Nuclear Medicine & Medical Imaging
- 3202 Clinical sciences
- 1103 Clinical Sciences